BPC-157: what the evidence actually shows

BPC-157 is a synthetic fragment of a protein found in gastric juice. Search PubMed and you will find a substantial body of work: it accelerates tendon-to-bone healing in rats, protects rodent gut, improves outcomes in rat models of nearly everything. Search PubMed with the filter for randomized controlled trials in humans and you will find nothing.

A large share of the published work traces to a single research group, and much of it is published in a narrow set of journals. That is not an accusation of dishonesty. It is a description of a literature that has not been independently replicated at scale, which is a materially different thing from a literature that has.

A 2026 review in Sports Med of approved and unapproved peptide therapies for musculoskeletal injury reaches the conclusion you would expect from the above: the human evidence for the unapproved peptides in this space does not support their use, however plausible the mechanism.

BPC-157 appears to promote angiogenesis — the growth of new blood vessels — and to modulate nitric oxide signalling and growth-factor pathways involved in tissue repair. Vascular supply genuinely is the limiting factor in healing tendon and ligament, which are poorly perfused. So the story is coherent, and coherence is seductive.

A plausible mechanism is a reason to run a trial. It is not a substitute for having run one. The history of medicine is a long list of mechanistically beautiful interventions that did nothing, or harmed people, when finally tested against a placebo in a randomised design.

A 2026 review in Pharmaceutics examined BPC-157 as an investigational therapeutic and catalogued its biopharmaceutical challenges — stability, formulation, and characterisation problems that would have to be solved before any serious clinical programme. These are the unglamorous obstacles that stand between a promising rodent result and a medicine.

FDA reached the same territory from the regulatory side. It has stated that compounded drugs containing BPC-157 may pose a risk for immunogenicity for certain routes of administration, may have complexities regarding peptide-related impurities and active-ingredient characterisation, and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans." Its nomination for compounding was subsequently withdrawn by the nominators — which removed the question rather than answering it.

The truthful summary is: unknown in humans. Not "promising", which implies a direction. Not "ineffective", which implies a trial found nothing. Unknown.

That is a genuinely uncomfortable answer, and it is why every website selling BPC-157 gives you a different one. If a page tells you what BPC-157 does for human tendon healing, ask it to name the trial. There is not one to name.